# **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40001605 (16852)	<b>RISNo./Status :</b>	4017445/
Patient Name :	Mr. RAJESH KUMAR SHARMA	Age/Gender :	59 Y/M
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:34AM/ OPSCR23- 24/9339	Scan Date :	
<b>Report Date :</b>	15/12/2023 10:32AM	Company Name:	Mediwheel - Arcofemi Health Care Ltd.

# **USG REPORT - ABDOMEN AND PELVIS**

### LIVER:

Is normal in size and uniform echo texture.

No obvious focal lesion seen. No intra hepatic biliary radical dilatation seen.

### GALL BLADDER:

Adequately distended with no obvious wall thickening/pericholecystic fat stranding/fluid. No obvious calculus/polyp/mass seen within.

### PANCREAS:

Is obscured by bowel gases.

### **SPLEEN:**

Appears normal in size and it shows uniform echo texture.

### **RIGHT KIDNEY:**

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation. No calculi seen.

### **LEFT KIDNEY:**

The shape, size and contour of the left kidney appear normal. Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation. No calculi seen.

#### **URINARY BLADDER:**

Is normal in contour. No intraluminal echoes are seen. No calculus or diverticulum is seen. **PROSTATE:** 

### Is borderline enlarged in size, measuring approx. 25-27cc in volume.

No focal fluid collections seen.

#### **IMPRESSION:**

Borderline prostatomegaly.

Rem Jadiys

DR. RENU JADIYA Consultant – Radiology MBBS, DNB

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40001605 (16852)	<b>RISNo./Status :</b>	4017445/
Patient Name :	Mr. RAJESH KUMAR SHARMA	Age/Gender :	59 Y/M
<b>Referred By :</b>	EHS CONSULTANT	Ward/Bed No :	OPD
Bill Date/No :	15/12/2023 8:34AM/ OPSCR23- 24/9339	Scan Date :	
<b>Report Date :</b>	15/12/2023 12:19PM	Company Name:	Provisional

#### **REFERRAL REASON: HEALTH CHECKUP**

#### **2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER**

#### **M MODE DIMENSIONS: -**

			No	rmal				Normal
IVSD	12.0		6-1	l2mm		LVIDS	28.4	20-40mm
LVIDD	44.3		32-57mm		LVPWS	19.7	mm	
LVPWD	11.6		6-1	l2mm		AO	37.6	19-37mm
IVSS	19.3		]	mm		LA	36.6	19-40mm
LVEF	62-64		>	55%		RA	-	mm
	<b>DOPPLER MEASUREMENTS &amp; CALCULATIONS:</b>							
STRUCTURE	MORPHOLOGY	VELOCITY (m/s)		GRAD	IENT	REGURGITATION		
					(mml	H <u>g)</u>		
MITRAL	NORMAL	Ε	0.83	e'	0.06	-		TRIVIAL MR
VALVE		Α	0.64	E/e'	13.8			
TRICUSPID	NORMAL		Е	0.	68	-		NIL
VALVE			Α	0.	68			
AORTIC	NORMAL		1	1.21		-		NIL
VALVE								
PULMONARY	NORMAL		(	0.84				NIL
VALVE						-		

#### COMMENTS & CONCLUSION: -

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- GRADE I LV DIASTOLIC DYSFUNCTION
- TRIVIAL MR, OTHER CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

# IMPRESSION: - TRIVIAL MR, GRADE I LV DIASTOLIC DYSFUNCTION, NORMAL BI VENTRICULAR SYSTOLIC FUNCTION

DR SUPRIY JAIN MBBS, M.D., D.M. (CARDIOLOGY) INCHARGE & SR. CONSULTANT INTERVENTIONAL CARDIOLOGY DR ROOPAM SHARMA MBBS, PGDCC, FIAE CONSULTANT & INCHARGE EMERGENCY, PREVENTIVE CARDIOLOGY AND WELLNESS CENTRE

Patient Name	Mr. RAJESH KUMAR SH	ARMA		Lab No	4017445	
UHID	40001605			Collection Date	15/12/2023 8:5	
Age/Gender	59 Yrs/Male			Receiving Date	15/12/2023 9:3	3AM
IP/OP Location	O-OPD			Report Date	15/12/2023 2:5	4PM
Referred By	EHS CONSULTANT			Report Status	Final	
Mobile No.	9772157693					
			BIOCHEMISTR	Υ		
Test Name		Result	Unit	Biolog	ical Ref. Range	
BLOOD GLUCOSE (F	ASTING)					Sample: Fl. Plasma
BLOOD GLUCOSE (F	ASTING)	90.3	mg/dl	74 - 106		
Method: Hexokinas Interpretation:-D various diseases.	iagnosis and monitoring	of treatment in	diabetes mellitus	and evaluation of c	arbohydrate metabo	lism in
BLOOD GLUCOSE (F	PP )					Sample: PLASMA
BLOOD GLUCOSE (P	Ρ)	115.8	mg/dl		tic: - < 140 mg/dl ic: - 140-199 mg/dl =200 mg/dl	
Method: Hexokinas Interpretation:-D various diseases.	iagnosis and monitoring	of treatment in	diabetes mellitus	and evaluation of c	arbohydrate metabo.	lism in
LFT (LIVER FUNCTIO	<u>ON TEST)</u>					Sample: Serum
BILIRUBIN TOTAL		0.55	mg/dl	0.00 - 1.20		
BILIRUBIN INDIREC	т	0.40	mg/dl	0.20 - 1.00		
BILIRUBIN DIRECT		0.15	mg/dl	0.00 - 0.40		
SGOT		26.5	U/L	0.0 - 40.0		
SGPT		25.3	U/L	0.0 - 40.0		
		2010	0/ 2	0.0 1010		

g/dl

g/dl

U/L

Ratio U/L 6.6 - 8.7

3.5 - 5.2

1.8 - 3.6

41 - 137

1.5 - 2.5

10.0 - 55.0

7.1

4.3

2.8

44.7

1.5

24.2

**RESULT ENTERED BY : SUNIL EHS** 

AldrinayVerna

Dr. ABHINAY VERMA

TOTAL PROTEIN

ALKALINE PHOSPHATASE

ALBUMIN

GLOBULIN

A/G RATIO

GGTP

Patient Name	Mr. RAJESH KUMAR SHARMA	Lab No	4017445
UHID	40001605	Collection Date	15/12/2023 8:57AM
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### BIOCHEMISTRY

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

**BILIRUBIN DIRECT** :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS :- Method: Biuret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder. ALBUMIN :- Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE :- Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GCTP-GAMMA GLUTAWIL TRANSPEPTIDASE :- Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	188		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	62.5		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	92.4		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	14	mg/dl	10 - 50
TRIGLYCERIDES	70.8		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	3.0	%	

**RESULT ENTERED BY : SUNIL EHS** 

AlbinayVen

Dr. ABHINAY VERMA

Patient Name	Mr. RAJESH KUMAR SHARMA	Lab No	4017445
UHID	40001605	Collection Date	15/12/2023 8:57AM
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### BIOCHEMISTRY

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders.

HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method. Interpretation:-HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease.

LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay. Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are

Synthesized in the liver. CHOLESTEROL VLDL :- Method: VLDL Calculative

Interpretation:-High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

UREA	17.30	mg/dl	16.60 - 48.50
BUN	8.1	mg/dl	6 - 20
CREATININE	0.90	mg/dl	0.60 - 1.10
SODIUM	141.7	mmol/L	136 - 145
POTASSIUM	4.37	mmol/L	3.50 - 5.50
CHLORIDE	99.4	mmol/L	98 - 107
URIC ACID	3.5	mg/dl	3.5 - 7.2
CALCIUM	9.34	mg/dl	8.60 - 10.30

**RESULT ENTERED BY : SUNIL EHS** 



**Dr. ABHINAY VERMA** 

MBBS | MD | INCHARGE PATHOLOGY

Sample: Serum

Patient Name UHID	Mr. RAJESH KUMAR SHARMA 40001605	Lab No Collection Date	4017445 15/12/2023 8:57AM
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

**CREATININE - SERUM** :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease. **URIC ACID** :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake andkidney reabsorption.

**POTASSIUM** :- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure. **CHLORIDE - SERUM** :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced

CHLORIDE - SERUM :- Method: ISE electrode. Interpretation:-Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning.

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL :- Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usuallyassociated with hypercalcemia. Increased serum calcium levels may also beobserved in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

**RESULT ENTERED BY : SUNIL EHS** 

Patient Name	Mr. RAJESH KUMAR SHARMA	Lab No Collection Date	4017445 15/12/2023 8:57AM
UHID Age/Gender	40001605 59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### **BLOOD BANK INVESTIGATION**

Test Name	Result	Unit	Biological Ref. Range
BLOOD GROUPING	"A" Rh Positive		

**BLOOD GROUPING** 

Note :

Both forward and reverse grouping performed.
Test conducted on EDTA whole blood.

**RESULT ENTERED BY : SUNIL EHS** 

AllineyVana

Dr. ABHINAY VERMA

Patient Name UHID	Mr. RAJESH KUMAR SHARMA 40001605	Lab No Collection Date	4017445 15/12/2023 8:57AM	
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM	
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM	
Referred By	EHS CONSULTANT	Report Status	Final	
Mobile No.	9772157693			

#### **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
РН	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.005		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	1-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

**RESULT ENTERED BY : SUNIL EHS** 

AlbunayVana

Dr. ABHINAY VERMA

Patient Name	Mr. RAJESH KUMAR SHARMA	Lab No	4017445
UHID	40001605	Collection Date	15/12/2023 8:57AM
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

#### **CLINICAL PATHOLOGY**

BACTERIA	NIL	NIL
OHTERS	NIL	NIL

Methodology:-

Methodology:-Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue (Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method. interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

**RESULT ENTERED BY : SUNIL EHS** 

Alerinary Van

**Dr. ABHINAY VERMA** 

Patient Name UHID	Mr. RAJESH KUMAR SHARMA 40001605	Lab No Collection Date	4017445 15/12/2023 8:57AM
Age/Gender	59 Yrs/Male O-OPD	Receiving Date Report Date	15/12/2023 9:33AM
IP/OP Location Referred By	EHS CONSULTANT	Report Status	15/12/2023 2:54PM Final
Mobile No.	9772157693		

#### HEMATOLOGY

Test Name	Result	Unit	Biological Ref. Ra	nge
CBC (COMPLETE BLOOD COUNT)				Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	12.0 L	g/dl	13.0 - 17.0	
PACKED CELL VOLUME(PCV)	38.5 L	%	40.0 - 50.0	
MCV	90.0	fl	82 - 92	
МСН	28.0	pg	27 - 32	
МСНС	31.2 L	g/dl	32 - 36	
RBC COUNT	4.28 L	millions/cu.mm	4.50 - 5.50	
TLC (TOTAL WBC COUNT)	6.37	10^3/ uL	4 - 10	
DIFFERENTIAL LEUCOCYTE COUNT				
NEUTROPHILS	74.6	%	40 - 80	
LYMPHOCYTE	13.5 L	%	20 - 40	
EOSINOPHILS	4.1	%	1 - 6	
MONOCYTES	7.2	%	2 - 10	
BASOPHIL	0.6 L	%	1 - 2	
PLATELET COUNT	2.28	lakh/cumm	1.500 - 4.500	

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia. MCV :- Method:- Calculation bysysmex. MCH :- Method:- Calculation bysysmex. MCHC :- Method:- Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia,High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method:-Optical Detectorblock based on Flowcytometry.Interpretation:-High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry

LYMPHOCYTS :- Method: Optical detectorblock based on Flowcytometry

EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry

BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE)

45 H

mm/1st hr 0 - 15

**RESULT ENTERED BY : SUNIL EHS** 

AlerinaryVan

#### **Dr. ABHINAY VERMA**

Patient Name UHID	Mr. RAJESH KUMAR SHARMA 40001605	Lab No Collection Date	4017445 15/12/2023 8:57AM
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
IP/OP Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

Method:-Modified Westergrens. Interpretation:-Increased in infections, sepsis, and malignancy.

**RESULT ENTERED BY : SUNIL EHS** 

Patient Name	Mr. RAJESH KUMAR SHARMA	Lab No	4017445
UHID	40001605	Collection Date	15/12/2023 8:57AM
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 9:33AM
<b>IP/OP</b> Location	O-OPD	Report Date	15/12/2023 2:54PM
Referred By	EHS CONSULTANT	Report Status	Final
Mobile No.	9772157693		

X Ray

Unit

**Test Name** 

Result

**Biological Ref. Range** 

# X-RAY - CHEST PA VIEW

### **OBSERVATION:**

### Rotation noted.

The mediastinal and cardiac silhouette are normal.

Cardiothoracic ratio is normal.

Cardiophrenic and costophrenic angles are normal.

Both hila are normal.

The lung fields are clear.

Bones of the thoracic cage are normal.

\*\*End Of Report\*\*

**RESULT ENTERED BY : SUNIL EHS** 

Rundad

Dr. RENU JADIYA MBBS, DNB RADIOLOGIST

Patient Name	Mr. RAJESH KUMAR SHARMA	Lab No	587436	ALL
UHID	331343	Collection Date	15/12/2023 10:15AM	
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 10:16AM	
IP/OP Location	O-OPD	Report Date	15/12/2023 12:02PM	
Referred By	Dr. EHCC Consultant	Report Status	Final	MC-2561
Mobile No.	9773349797			

#### BIOCHEMISTRY

Test Name THYROID T3 T4 TSH	Result	Unit	Biological Ref. Range	Sample: Serum
ТЗ	1.05	ng/mL	0.800 - 2.000	•
Τ4	7.20	ug/dl	5.10 - 14.10	
TSH	9.51 H	μIU/mL	0.27 - 5.20	

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages of hyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation:-The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater oppositechanges in the TSH levels.

\*\*End Of Report\*\*

**RESULT ENTERED BY : Mr. PANKAJ SHUKLA** 

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS [MD] PATHOLOGY



Dr. ASHISH SHARMA CONSULTANT & INCHARGE PATHOLOGY MBBS|MD| PATHOLOGY

Page: 1 Of 1

Patient Name UHID	Mr. RAJESH KUMAR SHARMA 331343	Lab No Collection Date	587436 15/12/2023 10:15AM	
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 10:16AM	ALL PROPERTY AND ADDRESS OF ADDRE
IP/OP Location	O-OPD	Report Date	15/12/2023 11:45AM	MC-2561
Referred By	Dr. EHCC Consultant	Report Status	Final	WIG-2301
Mobile No.	9773349797			
BIOCHEMISTRY				

Test Name	Result	Unit	Biological Ref. Range
			Sample: WHOLE BLOOD EDTA
HBA1C	6.1	%	< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes
			Known Diabetic Patients < 7 % Excellent Control
			7 - 8 % Good Control   > 8 % Poor Control

Method : - High - performance liquid chromatography HPLC Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbAlC and mean blood glucose values during the preceding 2 to 3 months.

\*\*End Of Report\*\*

**RESULT ENTERED BY : Mr. MAHENDRA KUMAR** 

Dr. SURENDRA SINGH **CONSULTANT & HOD** MBBS | MD | PATHOLOGY



Dr. ASHISH SHARMA **CONSULTANT & INCHARGE PATHOLOGY** MBBS | MD | PATHOLOGY

Patient Name UHID	Mr. RAJESH KUMAR SHARMA 331343	Lab No Collection Date	587436 15/12/2023 10:15AM	ALL DE LE
Age/Gender	59 Yrs/Male	Receiving Date	15/12/2023 10:16AM	
IP/OP Location	O-OPD	Report Date	15/12/2023 11:54AM	MC-2561
Referred By	Dr. EHCC Consultant	Report Status	Final	WIC-2381
Mobile No.	9773349797			
BIOCHEMISTRY				

Test Name	Result	Unit	Biological Ref. Range	
				Sample: Serum
PSA (TOTAL)	1.74	ng/mL	0.00 - 4.00	

Total (Free + complexed) PSA - Prostate specific antigen (tPSA)

Method : ElectroChemiLuminescence ImmunoAssay - ECLIA Interpretation:-PSA determinations are employed are the monitoring of progress and efficiency of therapy in patients with prostate carcinoma or receiving hormonal therapy.

\*\*End Of Report\*\*

**RESULT ENTERED BY : Mr. MAHENDRA KUMAR** 

Dr. SURENDRA SINGH **CONSULTANT & HOD** MBBS | MD | PATHOLOGY



Dr. ASHISH SHARMA **CONSULTANT & INCHARGE PATHOLOGY** MBBS | MD | PATHOLOGY